May 24th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the use of brentuximab vedotin in patients with Hodgkin lymphoma. This is the second of 2 articles based on this event.
Researchers Explore Novel Treatment Strategies CNS Lymphoma
March 30th 2023In an interview with Targeted Oncology, Craig Sauter, MD, discusses available treatments for patients with central nervous system lymphoma and research that will provide more developments moving forward in this space.
Read More
FDA’s ODAC Votes for Polatuzumab Plus R-CHP for Previously Untreated DLBCL
March 9th 2023In a vote of 11 to 2, the FDA's Oncologic Drugs Advisory Committee voted for the benefit/risk profile of polatuzumab vedotin in combination with R-CHP, based on findings from the confirmatory POLARIX trial.
Read More
New Solutions Continue to Show Up in the Lymphoma Treatment Landscape
March 9th 2023In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.
Read More
Discussing Current and Potential Expansions to the Lymphoma Treatment Landscape
March 2nd 2023In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.
Read More
Addition of Bortezomib Shows Efficacy/Safety in Waldenström's Macroglobulinemia
February 15th 2023A phase 3 trial of bortezomib, dexamethasone, rituximab, and cyclophosphamide shortened the median time to first response and increased the number of patients with Waldenström's macroglobulinemia.
Read More
Perez on Real-World Pola-BR Treatment Outcomes in Patients with R/R LBCL
January 16th 2023In an interview with Targeted Oncology, Ariel Perez, MD, explained the outcomes of patients with R/R large B-cell lymphoma who were treated with Pola-BR in the real-world setting, and the key takeaways from a single-institution study.
Read More
Addition of Polatuzumab to R-CHOP Improves Outcomes for Patients With DLBCL
January 10th 2023In an interview with Targeted Oncology, Gustavo Fonseca, MD, FACP, discussed the positive health-related quality of life findings in patients with diffuse large B-cell lymphoma from the POLARIX study.
Read More
Glofitamab Leads to Durable Complete Remissions in Relapsed/Refractory LBCL
January 6th 2023In an interview with Targeted Oncology, Cyrus M. Khan, MD, further discussed the background of the phase 1/2 trial and the potential use of glofitamab for patients with large B-cell lymphoma in the future.
Read More
HD-ASCT Shows Longer Survival Vs Non-Myeloablative Chemoimmunotherapy in Primary CNS Lymphoma
December 13th 2022An extended progression-free survival and 54% reduction in the risk of death was shown with high-dose chemotherapy autologous stem cell transplantation consolidation therapy vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.
Read More
Lenalidomide/ Rituximab Extends 5-Year PFS on R/R Indolent Non-Hodgkin Lymphoma
December 11th 2022Five-year follow up results from the phase 3 AUGMENT trial show that lenalidomide plus rituximab produced enhanced progression-free survival in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Read More
ECHELON-1 Trial of Brentuximab Vedotin Improves OS in Classical Hodgkin Lymphoma
December 7th 2022In an interview with Targeted Oncology, David J. Straus, MD, discussed the newest data of the ECHELON-1 trial which he presented at the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.
Read More